This study looks at how safe and effective a new drug called REC-4881 is for patients with certain types of cancer. The drug is for people with a specific gene change, called a mutation, in either AXIN1 or APC. These are genes that help control cell growth. The study is open-label, meaning both doctors and patients know they are getting the drug. Participants will take 12 mg of the drug by mouth every day for up to two years. The study will involve about 60 people, split into two groups based on their gene mutation. To join, you must be 55 or older, have a certain type of tumor that can't be removed by surgery, and have tried other cancer treatments without success. You cannot join if you've recently taken a similar drug or have a low heart function.

• This study lasts up to 2 years, with daily medication.
• Participants must have specific gene changes in their cancer.
• Some past treatments and heart issues may exclude participation.